ELV
Elevance Health, Inc.
Price Chart
Latest Quote
$370.10
-2.75 (-0.74%)
Current Price
| Previous Close | $372.85 |
| Open | $371.70 |
| Day High | $377.76 |
| Day Low | $365.38 |
| Volume | 1,115,379 |
Stock Information
| Quarterly Dividend / Yield | $6.88 / 1.85% |
| Shares Outstanding | 216.87M |
| Quarterly Dividend Yield | 1.85% |
| Quarterly Dividend | $6.88 |
| Total Debt | $31.04B |
| Cash Equivalents | $37.51B |
| Revenue | $201.11B |
| Net Income | $4.96B |
| Sector | Healthcare |
| Industry | Healthcare Plans |
| Market Cap | $80.92B |
| P/E Ratio | 16.50 |
| EPS (TTM) | $22.61 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $74.97B |
| Sales | $201.11B |
| Income | $4.96B |
| Book/sh | $205.98 |
| Cash/sh | $172.98 |
| Employees | 96K |
Financial Ratios
| Quick Ratio | 1.38 |
| Current Ratio | 1.52 |
| Debt/Eq | 68.95 |
| EPS Growth TTM | -16.10% |
Returns & Margins
| ROA | 3.83% |
| ROE | 11.13% |
| Gross Margin | 25.99% |
| Operating Margin | 4.56% |
| Profit Margin | 2.47% |
Ownership
| Insider Ownership | 0.18% |
| Institutional Ownership | 93.54% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 12.58 |
| PEG | 1.56 |
| P/S | 0.40 |
| P/B | 1.81 |
Analyst Data
| Recommendation | buy |
| Target Price | $447.62 |
Technical Indicators
| SMA20 | $401.09 |
| SMA50 | $397.29 |
| SMA200 | $346.73 |
| RSI | 41.89 |
| ATR | 16.0329 |
| Shares Float | 217.44M |
| Short Float | 3.10% |
| Short Ratio | 3.32 |
| Volatility | 0.68 |
| Rel Volume | 1.02 |
Performance History
| Week | -10.36% |
| Month | -6.21% |
| Quarter | +18.62% |
| 6 Months | +1.10% |
| YTD | +6.40% |
| Year | +10.56% |
| 3 Years | -5.37% |
| 5 Years | +3.16% |
| 10 Years | +217.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $373.11 | 1,924,800 |
| 2026-07-16 | $372.85 | 2,902,800 |
| 2026-07-15 | $390.33 | 3,897,300 |
| 2026-07-14 | $426.79 | 2,192,600 |
| 2026-07-13 | $425.17 | 1,244,800 |
| 2026-07-10 | $416.23 | 779,500 |
| 2026-07-09 | $420.39 | 1,062,400 |
| 2026-07-08 | $416.08 | 1,280,100 |
| 2026-07-07 | $418.85 | 1,225,000 |
| 2026-07-06 | $408.17 | 1,680,300 |
| 2026-07-02 | $417.89 | 1,626,200 |
| 2026-07-01 | $416.19 | 2,106,500 |
| 2026-06-30 | $386.73 | 1,841,800 |
| 2026-06-29 | $388.03 | 1,222,700 |
| 2026-06-26 | $395.18 | 2,913,700 |
| 2026-06-25 | $387.32 | 1,762,800 |
| 2026-06-24 | $384.00 | 2,166,700 |
| 2026-06-23 | $395.10 | 1,257,000 |
| 2026-06-22 | $394.82 | 1,172,000 |
| 2026-06-18 | $388.50 | 3,536,900 |
About Elevance Health, Inc.
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
đ° Latest News
Elevance Health CEO Snaps Up Stock After Post-Earnings Slide
Barrons.com âĸ 2026-07-17T22:20:00Z
What A Patient Holder Is Really Paying For CVS Health Stock
Trefis âĸ 2026-07-17T22:09:52Z
What's A Strong Quarter Worth When Elevance Health Is Ditching Its Own Markets?
Trefis âĸ 2026-07-17T22:02:00Z
Elevance Health CEO Boudreaux Buys $1 Million in Shares. What Does This Mean For its 2026 Outlook?
Motley Fool âĸ 2026-07-17T19:55:43Z
Big Hospital Systems Are Dropping Medicare Advantage Plans Mid-Contract. Patients Find Out by Letter
24/7 Wall St. âĸ 2026-07-16T22:25:57Z
Why UNH Stock Breakout Faltered After Massive Earnings Beat
Investor's Business Daily âĸ 2026-07-16T19:27:37Z
UnitedHealth stock jumps on Q2 earnings, raises full-year outlook
Yahoo Finance Video âĸ 2026-07-16T14:54:04Z
Elevance Health (ELV) Stock Sees Modest Fair Value Lift As Analysts Turn More Constructive
Simply Wall St. âĸ 2026-07-16T14:14:26Z
The Medicaid Problem That Swallowed an Earnings Beat
Trefis âĸ 2026-07-16T13:19:55Z
The Medicaid Problem Weighing On Elevance Health Stock
Trefis âĸ 2026-07-16T12:30:32Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $199,125,000,000 | $176,810,000,000 | $171,340,000,000 | $156,595,000,000 |
| Operating Revenue | $199,125,000,000 | $176,810,000,000 | $171,340,000,000 | $156,595,000,000 |
| Expenses | ||||
| Interest Expense | $1,402,000,000 | $1,185,000,000 | $1,030,000,000 | $851,000,000 |
| Total Expenses | $192,415,000,000 | $168,906,000,000 | $163,625,000,000 | $148,995,000,000 |
| Other Income Expense | $24,470,000,000 | $22,630,000,000 | $19,452,000,000 | $14,978,000,000 |
| Net Non Operating Interest Income Expense | $-1,402,000,000 | $-1,185,000,000 | $-1,030,000,000 | $-851,000,000 |
| Interest Expense Non Operating | $1,402,000,000 | $1,185,000,000 | $1,030,000,000 | $851,000,000 |
| Other Operating Expenses | $42,162,000,000 | $39,775,000,000 | $37,380,000,000 | $30,735,000,000 |
| Loss Adjustment Expense | $148,223,000,000 | $127,567,000,000 | $124,330,000,000 | $116,642,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $5,662,000,000 | $5,980,000,000 | $5,987,000,000 | $5,894,000,000 |
| Net Interest Income | $-1,402,000,000 | $-1,185,000,000 | $-1,030,000,000 | $-851,000,000 |
| Normalized Income | $5,662,000,000 | $5,828,245,000 | $5,987,000,000 | $5,894,000,000 |
| Net Income From Continuing And Discontinued Operation | $5,662,000,000 | $5,980,000,000 | $5,987,000,000 | $5,894,000,000 |
| Net Income Common Stockholders | $5,662,000,000 | $5,980,000,000 | $5,987,000,000 | $5,894,000,000 |
| Net Income | $5,662,000,000 | $5,980,000,000 | $5,987,000,000 | $5,894,000,000 |
| Net Income Including Noncontrolling Interests | $5,661,000,000 | $5,971,000,000 | $5,991,000,000 | $5,888,000,000 |
| Net Income Continuous Operations | $5,661,000,000 | $5,971,000,000 | $5,991,000,000 | $5,888,000,000 |
| Pretax Income | $6,710,000,000 | $7,904,000,000 | $7,715,000,000 | $7,600,000,000 |
| Special Income Charges | $0 | $201,000,000 | $0 | $0 |
| Depreciation And Amortization In Income Statement | $628,000,000 | $580,000,000 | $885,000,000 | $767,000,000 |
| Per Share | ||||
| Diluted EPS | $25.21 | $25.68 | $25.22 | $24.81 |
| Basic EPS | $25.65 | $26.29 | $25.69 | $25.32 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $49,245,000 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Total Unusual Items | $0 | $201,000,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $201,000,000 | $0 | $0 |
| Reconciled Depreciation | $1,546,000,000 | $1,393,000,000 | $1,745,000,000 | $1,675,000,000 |
| EBIT | $8,112,000,000 | $9,089,000,000 | $8,745,000,000 | $8,451,000,000 |
| Diluted Average Shares | $224,600,000 | $232,900,000 | $237,400,000 | $242,800,000 |
| Basic Average Shares | $220,723,898 | $227,479,695 | $233,071,088 | $237,958,067 |
| Diluted NI Availto Com Stockholders | $5,662,000,000 | $5,980,000,000 | $5,987,000,000 | $5,894,000,000 |
| Minority Interests | $1,000,000 | $9,000,000 | $-4,000,000 | $6,000,000 |
| Tax Provision | $1,049,000,000 | $1,933,000,000 | $1,724,000,000 | $1,712,000,000 |
| Amortization | $628,000,000 | $580,000,000 | $885,000,000 | $767,000,000 |
| Net Policyholder Benefits And Claims | $148,223,000,000 | $127,567,000,000 | $124,330,000,000 | $116,642,000,000 |
| Policyholder Benefits Gross | $148,295,000,000 | $127,623,000,000 | $124,393,000,000 | $116,694,000,000 |
| Policyholder Benefits Ceded | $72,000,000 | $56,000,000 | $63,000,000 | $52,000,000 |
| Other Special Charges | - | $-201,000,000 | - | - |
| Selling General And Administration | - | - | - | $17,686,000,000 |
Fetched: 2026-07-10
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,338,000,000 | $944,000,000 | $3,716,000,000 | $1,545,000,000 |
| Total Assets | $121,494,000,000 | $116,889,000,000 | $108,928,000,000 | $102,755,000,000 |
| Goodwill And Other Intangible Assets | $39,544,000,000 | $40,371,000,000 | $35,590,000,000 | $34,698,000,000 |
| Other Intangible Assets | $11,200,000,000 | $12,094,000,000 | $10,273,000,000 | $10,315,000,000 |
| Receivables | $21,542,000,000 | $19,071,000,000 | $17,865,000,000 | $16,044,000,000 |
| Other Receivables | $11,469,000,000 | $11,060,000,000 | $9,963,000,000 | $8,961,000,000 |
| Accounts Receivable | $10,073,000,000 | $8,011,000,000 | $7,902,000,000 | $7,083,000,000 |
| Cash Cash Equivalents And Short Term Investments | $35,375,000,000 | $33,489,000,000 | $36,140,000,000 | $33,339,000,000 |
| Cash And Cash Equivalents | $9,491,000,000 | $8,288,000,000 | $6,526,000,000 | $7,387,000,000 |
| Debt | ||||
| Net Debt | $22,555,000,000 | $22,944,000,000 | $18,594,000,000 | $16,727,000,000 |
| Total Debt | $32,046,000,000 | $31,232,000,000 | $25,120,000,000 | $24,114,000,000 |
| Long Term Debt And Capital Lease Obligation | $30,797,000,000 | $29,218,000,000 | $23,246,000,000 | $22,349,000,000 |
| Long Term Debt | $30,797,000,000 | $29,218,000,000 | $23,246,000,000 | $22,349,000,000 |
| Current Debt And Capital Lease Obligation | $1,249,000,000 | $2,014,000,000 | $1,874,000,000 | $1,765,000,000 |
| Current Debt | $1,249,000,000 | $2,014,000,000 | $1,874,000,000 | $1,765,000,000 |
| Other Current Borrowings | $1,249,000,000 | $2,014,000,000 | $1,874,000,000 | $1,765,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $77,468,000,000 | $75,463,000,000 | $69,523,000,000 | $66,425,000,000 |
| Non Current Deferred Liabilities | $2,110,000,000 | $2,148,000,000 | $1,970,000,000 | $2,015,000,000 |
| Non Current Deferred Taxes Liabilities | $2,110,000,000 | $2,148,000,000 | $1,970,000,000 | $2,015,000,000 |
| Current Deferred Liabilities | $1,493,000,000 | $1,508,000,000 | $1,402,000,000 | $1,112,000,000 |
| Payables And Accrued Expenses | $24,406,000,000 | $22,673,000,000 | $23,021,000,000 | $21,203,000,000 |
| Payables | $24,406,000,000 | $22,673,000,000 | $23,021,000,000 | $21,203,000,000 |
| Accounts Payable | $24,406,000,000 | $22,673,000,000 | $23,021,000,000 | $21,203,000,000 |
| Equity | ||||
| Common Stock Equity | $43,882,000,000 | $41,315,000,000 | $39,306,000,000 | $36,243,000,000 |
| Total Equity Gross Minority Interest | $44,026,000,000 | $41,426,000,000 | $39,405,000,000 | $36,330,000,000 |
| Stockholders Equity | $43,882,000,000 | $41,315,000,000 | $39,306,000,000 | $36,243,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-451,000,000 | $-1,147,000,000 | $-1,313,000,000 | $-2,490,000,000 |
| Other Equity Adjustments | $-451,000,000 | $-1,147,000,000 | $-1,313,000,000 | $-2,490,000,000 |
| Retained Earnings | $35,393,000,000 | $33,549,000,000 | $31,749,000,000 | $29,647,000,000 |
| Other | ||||
| Ordinary Shares Number | $220,723,898 | $227,479,695 | $233,071,088 | $237,958,067 |
| Share Issued | $220,723,898 | $227,479,695 | $233,071,088 | $237,958,067 |
| Tangible Book Value | $4,338,000,000 | $944,000,000 | $3,716,000,000 | $1,545,000,000 |
| Invested Capital | $75,928,000,000 | $72,547,000,000 | $64,426,000,000 | $60,357,000,000 |
| Total Capitalization | $74,679,000,000 | $70,533,000,000 | $62,552,000,000 | $58,592,000,000 |
| Minority Interest | $144,000,000 | $111,000,000 | $99,000,000 | $87,000,000 |
| Additional Paid In Capital | $8,938,000,000 | $8,911,000,000 | $8,868,000,000 | $9,084,000,000 |
| Capital Stock | $2,000,000 | $2,000,000 | $2,000,000 | $2,000,000 |
| Common Stock | $2,000,000 | $2,000,000 | $2,000,000 | $2,000,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Deferred Revenue | $1,493,000,000 | $1,508,000,000 | $1,402,000,000 | $1,112,000,000 |
| Investments And Advances | $27,745,000,000 | $27,428,000,000 | $30,719,000,000 | $27,657,000,000 |
| Goodwill | $28,344,000,000 | $28,277,000,000 | $25,317,000,000 | $24,383,000,000 |
| Net PPE | $4,679,000,000 | $4,652,000,000 | $4,359,000,000 | $4,316,000,000 |
| Other Short Term Investments | $25,884,000,000 | $25,201,000,000 | $29,614,000,000 | $25,952,000,000 |
Fetched: 2026-07-10
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $3,174,000,000 | $4,552,000,000 | $6,765,000,000 | $7,247,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $4,290,000,000 | $5,808,000,000 | $8,061,000,000 | $8,399,000,000 |
| Cash Flow From Continuing Operating Activities | $4,290,000,000 | $5,808,000,000 | $8,061,000,000 | $8,399,000,000 |
| Operating Gains Losses | $255,000,000 | $243,000,000 | $727,000,000 | $257,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,116,000,000 | $-1,256,000,000 | $-1,296,000,000 | $-1,152,000,000 |
| Investing Cash Flow | $-1,344,000,000 | $-5,167,000,000 | $-5,572,000,000 | $-4,560,000,000 |
| Cash Flow From Continuing Investing Activities | $-1,344,000,000 | $-5,167,000,000 | $-5,572,000,000 | $-4,560,000,000 |
| Net Other Investing Changes | $-385,000,000 | $-51,000,000 | $-24,000,000 | $-421,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-2,605,000,000 | $-2,900,000,000 | $-2,676,000,000 | $-2,316,000,000 |
| Financing Cash Flow | $-1,738,000,000 | $1,193,000,000 | $-3,349,000,000 | $-1,318,000,000 |
| Cash Flow From Continuing Financing Activities | $-1,738,000,000 | $1,193,000,000 | $-3,349,000,000 | $-1,318,000,000 |
| Net Other Financing Charges | $-10,000,000 | $-107,000,000 | $-92,000,000 | $-52,000,000 |
| Cash Dividends Paid | $-1,529,000,000 | $-1,508,000,000 | $-1,395,000,000 | $-1,229,000,000 |
| Common Stock Dividend Paid | $-1,529,000,000 | $-1,508,000,000 | $-1,395,000,000 | $-1,229,000,000 |
| Net Common Stock Issuance | $-2,605,000,000 | $-2,900,000,000 | $-2,676,000,000 | $-2,316,000,000 |
| Other | ||||
| Repayment Of Debt | $-3,867,000,000 | $-2,498,000,000 | $-2,251,000,000 | $-3,574,000,000 |
| Issuance Of Debt | $6,194,000,000 | $7,985,000,000 | $2,913,000,000 | $5,369,000,000 |
| End Cash Position | $9,491,000,000 | $8,288,000,000 | $6,526,000,000 | $7,387,000,000 |
| Other Cash Adjustment Outside Changein Cash | $0 | $-66,000,000 | $0 | $0 |
| Beginning Cash Position | $8,288,000,000 | $6,526,000,000 | $7,387,000,000 | $4,880,000,000 |
| Effect Of Exchange Rate Changes | $-5,000,000 | $-6,000,000 | $-1,000,000 | $-14,000,000 |
| Changes In Cash | $1,208,000,000 | $1,834,000,000 | $-860,000,000 | $2,521,000,000 |
| Proceeds From Stock Option Exercised | $79,000,000 | $221,000,000 | $152,000,000 | $182,000,000 |
| Common Stock Payments | $-2,605,000,000 | $-2,900,000,000 | $-2,676,000,000 | $-2,316,000,000 |
| Net Issuance Payments Of Debt | $2,327,000,000 | $5,487,000,000 | $662,000,000 | $1,795,000,000 |
| Net Short Term Debt Issuance | $1,483,000,000 | $-573,000,000 | $-3,000,000 | $623,000,000 |
| Short Term Debt Payments | $-1,720,000,000 | $-848,000,000 | $-342,000,000 | $-1,675,000,000 |
| Short Term Debt Issuance | $3,203,000,000 | $275,000,000 | $339,000,000 | $2,298,000,000 |
| Net Long Term Debt Issuance | $844,000,000 | $6,060,000,000 | $665,000,000 | $1,172,000,000 |
| Long Term Debt Payments | $-2,147,000,000 | $-1,650,000,000 | $-1,909,000,000 | $-1,899,000,000 |
| Long Term Debt Issuance | $2,991,000,000 | $7,710,000,000 | $2,574,000,000 | $3,071,000,000 |
| Net Investment Purchase And Sale | $69,000,000 | $586,000,000 | $-2,700,000,000 | $-2,338,000,000 |
| Sale Of Investment | $15,095,000,000 | $18,572,000,000 | $13,536,000,000 | $22,608,000,000 |
| Purchase Of Investment | $-15,026,000,000 | $-17,986,000,000 | $-16,236,000,000 | $-24,946,000,000 |
| Net Business Purchase And Sale | $88,000,000 | $-4,446,000,000 | $-1,552,000,000 | $-649,000,000 |
| Sale Of Business | $88,000,000 | $363,000,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-1,116,000,000 | $-1,256,000,000 | $-1,296,000,000 | $-1,152,000,000 |
| Purchase Of PPE | $-1,116,000,000 | $-1,256,000,000 | $-1,296,000,000 | $-1,152,000,000 |
| Change In Working Capital | $-3,277,000,000 | $-1,719,000,000 | $-535,000,000 | $423,000,000 |
| Change In Other Working Capital | $-316,000,000 | $330,000,000 | $194,000,000 | $-446,000,000 |
| Change In Other Current Assets | $57,000,000 | $746,000,000 | $-754,000,000 | $144,000,000 |
| Change In Payables And Accrued Expense | $-720,000,000 | $-272,000,000 | $1,640,000,000 | $824,000,000 |
| Change In Payable | $-720,000,000 | $-272,000,000 | $1,640,000,000 | $824,000,000 |
| Change In Account Payable | $-720,000,000 | $-272,000,000 | $1,640,000,000 | $824,000,000 |
| Change In Receivables | $-2,526,000,000 | $-683,000,000 | $-1,762,000,000 | $-2,510,000,000 |
| Stock Based Compensation | $276,000,000 | $191,000,000 | $289,000,000 | $264,000,000 |
| Asset Impairment Charge | $108,000,000 | $103,000,000 | $446,000,000 | $7,000,000 |
| Deferred Tax | $-279,000,000 | $-374,000,000 | $-602,000,000 | $-115,000,000 |
| Deferred Income Tax | $-279,000,000 | $-374,000,000 | $-602,000,000 | $-115,000,000 |
| Depreciation And Amortization | $1,546,000,000 | $1,393,000,000 | $1,745,000,000 | $1,675,000,000 |
| Earnings Losses From Equity Investments | $-398,000,000 | $-1,000,000 | $33,000,000 | $-293,000,000 |
| Gain Loss On Investment Securities | $653,000,000 | $445,000,000 | $694,000,000 | $550,000,000 |
| Gain Loss On Sale Of Business | $0 | $-201,000,000 | $0 | $0 |
| Net Income From Continuing Operations | $5,661,000,000 | $5,971,000,000 | $5,991,000,000 | $5,888,000,000 |
| Purchase Of Business | - | $-4,809,000,000 | $-1,552,000,000 | $-649,000,000 |
Fetched: 2026-07-10